Structural and thermodynamic basis of Amprenavir/Darunavir and Atazanavir resistance in HIV-1 protease with mutations at residue 50

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4176-4184

  Mittal, Seema ^a   Bandaranayake, Rajinthna M ^a   King, Nancy M ^a   Prabu Jeyabalan, Moses ^a   Nalam, Madhavi N L ^a   Nalivaika, Ellen A ^a   Yilmaz, Nese Kurt ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE;

ANTIVIRAL RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTROPY; ENZYME ACTIVE SITE; ENZYME BINDING; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS;

ANTI-HIV AGENTS; CARBAMATES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION, MISSENSE; OLIGOPEPTIDES; POINT MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PYRIDINES; SULFONAMIDES; THERMODYNAMICS;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875798935     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03486-12     Document Type: Article

References (42)

1. Debouck C. 1992. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8:153-164.
2. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ, Emini E. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
3. Emini EA, Schleif WA, Deutsch P, Condra JH. 1996. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Adv. Exp. Med. Biol. 394:327-331.
4. Roberts NA. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9(Suppl 2):S27-S32.
5. Chou K-C, Tomasselli AG, Reardon IM, Heinrikson RL. 1996. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Proteins 24:51-72.
6. Henderson LE, Copeland TD, Sowder RC, Schultz AM, Oraszlan S. 1988. Human retroviruses, cancer and AIDS: approaches to prevention and therapy. Liss, New York, NY.
7. Pettit SC, Sheng N, Tritch R, Erickson-Vitanen S, Swanstrom R. 1998. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv. Exp. Med. Biol. 436:15-25.
8. Sadler BM, Stein DS. 2002. Clinical pharmacology and pharmacokinetics of amprenavir. Ann. Pharmacother. 36:102-118.
9. King NM, Prabu-Jeyabalan M, Wigerinck P, De Bethune M-P, Schiffer CA. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012-12021.
10. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF. 2000. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44:2093-2099.
11. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, Stuver CM, Byrn RA, Livingston DJ. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
12. Tisdale M, Myers RE, Ait-Khaled M, Snowden WA. 1999. HIV drug resistance analysis during clinical studies with the protease inhibitor amprenavir, abstr. 118. Abstr. Sixth Conf. Retroviruses Opportunistic Infect., Chicago, IL.
13. Van Marck H, Dierynck I, Kraus G, Hallenberger S, Pattery T, Muyldermans G, Van Vijmen H, Hertogs K, Bethune M. 2007. Unraveling the complex resistance pathways of darunavir using the bioinformatics resistance determination (BIRD). Antivir. Ther. 12:S141.
14. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P. 2007. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J. Virol. Methods 145:47-55.
15. Colonno R, Parkin N, McLaren C, Seekins D, Hodder S, Schnittman S, Kelleher T. 2004. Pathways to atazanavir resistance in treatmentexperienced patients and impact of residue 50 substitutions, abstr. 656. Abstr. Conf. Retroviruses Opportunistic Infect., San Francisco, CA.
16. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. 2004. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATVcontaining regimens. J. Infect. Dis. 189:1802-1810.
17. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. 2003.Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:298-303.
18. Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
19. Meher BR, Wang Y. 2012. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies. J. Phys. Chem. B 116:1884-1900.
20. Prabu-Jeyabalan M, Nalivaika E, King NM, Schiffer CA. 2004. Structual basis for coevolution of the human immunodeficiency virus type 1 nucleocapsid- p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78:12446-12454.
21. Rose JR, Salto R, Craik CS. 1993. Regulation of HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem. 268: 11939-11945.
22. King NM, Melnick L, Prabu-Jeyabalan M, Nalivaika EA, Yang S-S, Gao Y, Nie X, Zepp C, Heefner DL, Schiffer CA. 2002. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11:418-429.
23. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
24. Collaborative Computational Project Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
25. Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. 2006. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J. Virol. 80:3607-3616.
26. Painter J, Merritt EA. 2006. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62:439-450.
27. Jones TA, Bergdoll M, Kjeldgaard M. 1990. O: a macromolecular modeling environment, p 189-195. In Bugg C, Ealick S (ed), Crystallographic and modeling methods in molecular design. Springer-Verlag Press, Berlin, Germany.
28. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
29. DeLano WL. 2002. The PyMol molecular graphics system. DeLano Scientific, San Carlos, CA.
30. Nalam MN, Ali A, Altman MD, Reddy GS, Chellappan S, Kairys V, Ozen A, Cao H, Gilson MK, Tidor B, Rana TM, Schiffer CA. 2010. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 84:5368-5378.
31. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW. 2010. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 54:4253-4261.
32. Muzammil S, Armstrong AA, Kang LW, Jakalian A, Bonneau PR, Schmelmer V, Amzel LM, Freire E. 2007. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J. Virol. 81:5144-5154.
33. Yanchunas J, Jr, Langley DR, Tao L, Rose RE, Friborg J, Colonno RJ, Doyle ML. 2005. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors. Antimicrob. Agents Chemother. 49:3825-3832.
34. Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. 2005. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48:1813-1822.
35. Shen CH, Wang YF, Kovalevsky AY, Harrison RW, Weber IT. 2010. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J. 277:3699-3714.
36. Elston R, Scherer J, Schapiro J, Bethell R, Kohlbrenner V, Mayers D. 2006. De-selection for the I50V mutation occurs in clinical isolates during Aptivus/r (tipranavir/ritonavir) based therapy. Antivir. Ther. 11:S102.
37. Wainberg MA, Martinez-Cajas JL, Brenner BG. 2007. Strategies for the optimal sequencing of antiretroviral drugs toward overcoming and preventing drug resistance. Future HIV Ther. 1:291-313.
38. Brower ET, Bacha UM, Kawasaki Y, Freire E. 2008. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem. Biol. Drug Des. 71:298-305.
39. Agniswamy J, Shen CH, Aniana A, Sayer JM, Louis JM, Weber IT. 2012. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry 51:2819-2828.
40. Cai Y, Schiffer CA. 2010. Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV. J. Chem. Theory Comput. 6:1358-1368.
41. Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. 2011. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob. Agents Chemother. 55:1717-1727.
42. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369-381.